Background and aim: Teduglutide (TED), a synthetic analog of glucagon-like peptide 2, has been recently approved by the European Union to promote intestinal rehabilitation in pediatric patients with chronic intestinal failure secondary to short bowel syndrome. We aim to present the first series of paediatric patients treated in Argentina.

Material and methods: This is a retrospective review of a prospectively filled database, including every patient <18 years of age treated with TED at a single Intestinal Rehabilitation and Transplant Unit. Demographic data, diagnosis, nutritional status, parenteral support as % of the basal metabolic rate (no protein Kcal), intestinal anatomy, outcome and adverse effects are presented.

Results: From a total of 62 children with short bowel syndrome followed in the Unit, 4 patients started treatment with TED (dose 0.05 mg/kg/d, administered subcutaneously once a day). Table 1 shows baseline data and Table 2 follow up data.

Conclusions: TED treatment was well tolerated and has allowed, up to last follow up, achieving intestinal autonomy in half of the treated patients, and a significant PN requirement reduction in the rest. The four treated patients had been chronically PN dependent, and had failed other medical or surgical alternatives to reach intestinal autonomy.